We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+15.75%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.54B
AUM Growth
+$40.4M
Cap. Flow
-$337M
Cap. Flow %
-21.88%
Top 10 Hldgs %
46.87%
Holding
259
New
90
Increased
52
Reduced
41
Closed
65

Top Buys

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$25.6M
2
TMP icon
Tompkins Financial
TMP
+$13.1M
3
AGEN
Agenus
AGEN
+$6.13M
4
MNKD icon
MannKind Corp
MNKD
+$5.33M
5
MDVN
MEDIVATION, INC.
MDVN
+$3.71M

Top Sells

Rank Stock Value
1
AEGR
Aegerion Pharmaceuticals
AEGR
+$28.4M
2
ABBV icon
AbbVie
ABBV
+$14.7M
3
ZTS icon
Zoetis
ZTS
+$14.2M
4
TLT icon
iShares 20+ Year Treasury Bond ETF
TLT
+$11.5M
5
ARWR icon
Arrowhead Research
ARWR
+$8.75M

Sector Composition

Rank Sector Weight
1 Healthcare 10.49%
2 Financials 0.07%
3 Technology 0.07%
4 Energy 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRTX icon
1
CALL
Vertex Pharmaceuticals
VRTX
$124B
$189M 12.26%
24,890
+1,825
+8% +$145K
MRK icon
2
CALL
Merck
MRK
$326B
$82.2M 5.34%
18,086
+4,205
+30% +$192K
ACAD icon
3
CALL
Acadia Pharmaceuticals
ACAD
$4.45B
$82M 5.33%
29,842
+4,660
+19% +$97.4K
SRPT icon
4
PUT
Sarepta Therapeutics
SRPT
$1.63B
$61.5M 4%
13,028
+7,557
+138% +$291K
OEF icon
5
PUT
iShares S&P 100 ETF
OEF
$19.8B
$61M 3.97%
5,728
+3,728
+186% +$280K
EWA icon
6
PUT
iShares MSCI Australia ETF
EWA
$1.39B
$59.5M 3.87%
+50,000
New +$1.2M
GILD icon
7
PUT
Gilead Sciences
GILD
$167B
$53.5M 3.47%
8,506
+976
+13% +$58.3K
VRTX icon
8
PUT
Vertex Pharmaceuticals
VRTX
$124B
$49.7M 3.23%
6,551
+1,294
+25% +$103K
OEF icon
9
CALL
iShares S&P 100 ETF
OEF
$19.8B
$45.2M 2.94%
+4,250
New +$320K
SPY icon
10
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$783B
$37.8M 2.46%
2,250
-2,250
-50% -$377K
GSK icon
11
CALL
GSK
GSK
$108B
$32.8M 2.13%
+5,225
New +$336K
REGN icon
12
CALL
Regeneron Pharmaceuticals
REGN
$72.9B
$31.3M 2.04%
1,001
-1,136
-53% -$299K
MDVN
13
PUT
DELISTED
MEDIVATION, INC.
MDVN
$29.5M 1.92%
9,836
+7,308
+289% +$209K
BMY icon
14
CALL
Bristol-Myers Squibb
BMY
$130B
$28.4M 1.85%
6,139
+4,444
+262% +$195K
AEGR
15
PUT
DELISTED
Aegerion Pharmaceuticals
AEGR
$26.4M 1.72%
3,079
+709
+30% +$60.1K
VRTX icon
16
Vertex Pharmaceuticals
VRTX
$124B
$25.5M 1.66%
336,955
+321,847
+2,130% +$25.6M
SRPT icon
17
Sarepta Therapeutics
SRPT
$1.63B
$24.7M 1.6%
522,041
+67,142
+15% +$2.59M
AGN
18
CALL
DELISTED
Allergan Inc
AGN
$23M 1.49%
2,540
-1,059
-29% -$95.1K
AEGR
19
DELISTED
Aegerion Pharmaceuticals
AEGR
$22.2M 1.44%
259,119
-334,743
-56% -$28.4M
BIIB icon
20
CALL
Biogen
BIIB
$30.4B
$21M 1.37%
+874
New +$196K
MNKD icon
21
CALL
MannKind Corp
MNKD
$1.21B
$20M 1.3%
7,026
-734
-9% -$24.3K
AEGR
22
CALL
DELISTED
Aegerion Pharmaceuticals
AEGR
$18.9M 1.23%
2,200
+1,065
+94% +$90.3K
AGN
23
PUT
DELISTED
Allergan Inc
AGN
$18.4M 1.2%
2,033
+1,528
+303% +$137K
CELG
24
PUT
DELISTED
Celgene Corp
CELG
$18.1M 1.18%
2,356
+1,208
+105% +$84.7K
OPK icon
25
CALL
Opko Health
OPK
$1.23B
$16.8M 1.09%
+19,032
New +$153K
1
2 3 4 5

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q3 2013 Portfolio in Review

As of Q3 2013, Sabby Management held 259 positions worth $1.54B, up 2.7% from $1.5B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Sabby Management withdrew a net $337M in Q3 2013, closing 65 positions and reducing 41 holdings. Its most notable exit was AbbVie, an estimated $14.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 10% of assets, down from 11% a quarter earlier, followed by Financials and Technology.

Against the trend, Sabby Management opened a new position in Tompkins Financial worth $1.02M.

  • Sabby Management's largest Q3 2013 buy was Tompkins Financial: 288,454 shares worth $1.02M.
  • Sabby Management added most to Vertex Pharmaceuticals in Q3 2013, an estimated $25.6M increase.
  • Sabby Management's biggest Q3 2013 reduction was Aegerion Pharmaceuticals, cutting an estimated $28.4M.
  • Sabby Management fully exited AbbVie in Q3 2013, selling an estimated $14.7M.
  • Sabby Management's ten largest holdings make up 47% of its $1.54B portfolio in Q3 2013.
  • Sabby Management opened 90 new positions and closed 65 in Q3 2013.
  • Sabby Management's portfolio value rose 2.7% quarter-over-quarter to $1.54B.

Based on Sabby Management's 13F filing for Q3 2013, filed 14 Nov 2013.